By Fineline Cube 
Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into a strategic partnership to jointly develop a large-scale AI platform for biopharmaceutical research and development (R&D). The collaboration combines Mabwell’s expertise in biologics R&D with DP Technology’s advanced artificial intelligence (AI) capabilities, aiming to accelerate innovation in drug discovery and development.
Collaboration Details
The partnership focuses on two key initiatives:
- Knowledge Engine Development: Leveraging DP Technology’s Uni SMART multimodal scientific literature model, the collaboration will create a bio-innovative drug R&D knowledge engine. This engine will enable precise intelligent screening of scientific literature, identify and extract multimodal elements, and provide comprehensive and in-depth analysis to support drug development.
- Innovative Target Exploration: Utilizing DP Technology’s RiDYMO platform for high-quality hit discovery and optimization, the collaboration will unlock the dynamic mechanisms of challenging drug targets and explore a broader molecular chemical space, paving the way for novel therapeutic approaches.
Strategic Impact
By integrating advanced AI technologies with biopharmaceutical R&D, the collaboration aims to enhance efficiency and accuracy in identifying and validating drug targets. This initiative positions both companies at the forefront of innovation in the biopharmaceutical industry, driving the development of next-generation therapies.-Fineline Info & Tech